Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-P1B7
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-P1B7 is an experimental radiopharmaceutical consisting of the monoclonal antibody P1B7 conjugated to the beta-emitting radioisotope lutetium-177. P1B7 is a T-cell receptor-like (TCR-like) antibody specifically engineered to recognize a unique neoantigen: the KRAS G12C peptide covalently modified by the inhibitor sotorasib and presented on the cell surface by Major Histocompatibility Complex class I (MHC I) molecules. This approach repurposes sotorasib as a "hapten," allowing the antibody to target intracellular KRAS G12C oncoproteins that have been processed and displayed as drug-adducts. Developed by researchers at the University of California, San Francisco (UCSF), 177Lu-P1B7 is intended for use in combination with sotorasib to treat KRAS G12C-mutant cancers, potentially overcoming resistance to inhibitor monotherapy by delivering localized cytotoxic radiation directly to tumor cells.
- Other names
- 177Lu-P1B7 IgG
02
Targets
HLA-A*11
Beyond the preview
Go deeper on 177Lu-P1B7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-P1B7.